Literature DB >> 8395887

Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm.

F Leteurtre1, M Fesen, G Kohlhagen, K W Kohn, Y Pommier.   

Abstract

Camptothecin-induced DNA photolesions were examined after UVA irradiation at 365 nm. DNA single-strand breaks were induced both in supercoiled and in relaxed SV40 DNA. In uniquely end-labeled human c-myc DNA, camptothecin-induced cleavage occurred exclusively at guanines and was markedly enhanced by hot piperidine treatment. Runs of polyguanines were the most cleaved, especially in their 5' flank. Primer extension experiments in the absence of piperidine treatment confirmed these results and did not show additional lesions. We found that synthetic single-stranded oligonucleotides were more reactive than duplex oligonucleotides. In addition, an excess of dideoxyguanosine triphosphates competed for camptothecin-induced DNA photolesions. Therefore, camptothecin stacking in DNA grooves is more likely than genuine drug intercalation. Groove shielding with sodium or magnesium reduced camptothecin-induced photodamage while minor groove occupancy with spermine extended damages. Photolesion mechanisms were investigated using scavengers. In aerobic conditions, the most effective scavengers were thiourea, sodium azide, and catalase. Protection by superoxide dismutase was weak, and mannitol was ineffective. In anaerobic conditions, lesions were more extensive. Taken together, these results show that photoactivated camptothecin interacts specifically and intimately with guanines. This finding is consistent with preferential stimulation of topoisomerase I cleavage at sites that bear a guanine at their 5'-DNA terminus [Jaxel, C., et al. (1991) J. Biol. Chem. 266, 1465-1469] and with the camptothecin stacking model at topoisomerase I DNA cleavage sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8395887     DOI: 10.1021/bi00085a029

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  Position-specific trapping of topoisomerase I-DNA cleavage complexes by intercalated benzo[a]- pyrene diol epoxide adducts at the 6-amino group of adenine.

Authors:  Y Pommier; G S Laco; G Kohlhagen; J M Sayer; H Kroth; D M Jerina
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

Review 2.  Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?

Authors:  Fengzhi Li; Tao Jiang; Qingyong Li; Xiang Ling
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

3.  Electron paramagnetic resonance (EPR) study of spin-labeled camptothecin derivatives: a different look of the ternary complex.

Authors:  Antonio Ricci; Jessica Marinello; Marco Bortolus; Albert Sánchez; Anna Grandas; Enrique Pedroso; Yves Pommier; Giovanni Capranico; Anna Lisa Maniero; Giuseppe Zagotto
Journal:  J Med Chem       Date:  2011-01-21       Impact factor: 7.446

4.  Localization of an aminoacridine antitumor agent in a type II topoisomerase-DNA complex.

Authors:  C H Freudenreich; K N Kreuzer
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

5.  Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites.

Authors:  Y Pommier; G Kohlhagen; K W Kohn; F Leteurtre; M C Wani; M E Wall
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

6.  Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.

Authors:  R A Bras-Gonçalves; C Rosty; P Laurent-Puig; P Soulié; B Dutrillaux; M F Poupon
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.